Mar 31, 2026 4:15pm EDT FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
Mar 25, 2026 4:30pm EDT FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
Mar 12, 2026 8:30am EDT FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
Mar 05, 2026 8:30am EST FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Mar 02, 2026 8:30am EST FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
Feb 24, 2026 4:30pm EST FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update